When Steer Ballard didn't hear from her mom, Tamila Smith, for days, she kept calling until finally a police officer picked up. >> I said, "Who are you and what are you doing with my mom's phone?" And he stated, "Well, this is Glendale Police Department and I'm here with your mom's body." >> The officer told her that it appeared Smith had a surgery. >> Our bodies know what is best for us.After seeing her advertisements online, she'd gone to boardcertified plastic surgeon Heidi Regginus for lipos suction and ...

Core Viewpoint - Novo Nordisk has filed a lawsuit against Hims & Hers for infringing on its patent related to semaglutide products, claiming that Hims is marketing unapproved compounded versions that pose risks to patient safety [1][7]. Group 1: Legal Action and Patent Infringement - Novo Nordisk is taking legal action to protect its intellectual property and public health by seeking a permanent ban on Hims' sale of unapproved compounded drugs that infringe its patents [7]. - The lawsuit highlights Hims' promotional campaigns that mislead consumers and healthcare professionals regarding the safety and efficacy of its compounded semaglutide products [1][2]. Group 2: Patient Safety Concerns - Compounded semaglutide products marketed by Hims may contain dangerous impurities, with Novo Nordisk's testing revealing impurities of up to 86% in injectable forms and 75% in oral forms, which can lead to severe health risks [2][3]. - The FDA has stated that compounded GLP-1 drugs cannot be verified for quality, safety, or efficacy, raising significant concerns from medical organizations about the risks these knock-off drugs pose to patients [3]. Group 3: Company Initiatives and Market Position - Novo Nordisk emphasizes its commitment to patient safety and has launched educational campaigns to raise awareness about the dangers of unapproved drugs, including initiatives like "Check Before You Inject" [4]. - The company is ensuring that authentic, FDA-approved versions of Wegovy and Ozempic are readily available in the US, thereby discouraging patients from using unapproved alternatives [5].

Core Insights - Novo Nordisk has terminated its collaboration with Hims & Hers Health, Inc. due to non-compliance with legal standards regarding the sale of compounded drugs, which poses risks to patient safety [1][2][8] - The FDA has confirmed that Novo Nordisk is meeting the current and projected demand for Wegovy®, resolving previous shortages [2] - Novo Nordisk emphasizes the importance of providing authentic, FDA-approved Wegovy® to patients and is committed to working with telehealth companies that prioritize patient safety [3][8] Company Actions - Novo Nordisk will no longer provide Wegovy® through Hims & Hers Health, Inc. due to their deceptive marketing practices and illegal sales of compounded drugs [1][2][8] - The company is taking proactive measures to protect U.S. patients from unsafe knock-off drugs made with illicit foreign ingredients, particularly those sourced from unapproved suppliers in China [3][8] - Novo Nordisk aims to ensure that patients receive authentic Wegovy® through NovoCare® Pharmacy, which offers home delivery and support services [6][8] Industry Context - Obesity is recognized as a serious chronic disease affecting approximately 40% of adults in the U.S., necessitating long-term management and treatment options [5][23] - The prevalence of obesity has significant implications for healthcare systems, highlighting the need for effective and safe treatment options like Wegovy® [5][23] - The collaboration between telehealth companies and pharmaceutical firms is critical in providing access to regulated medications, but must adhere to legal and safety standards to protect patients [2][3][8]